Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04229004 · ClinicalTrials.gov registry record · Phase 3
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer
A Phase 3 study, sponsored by Pancreatic Cancer Action Network.
- Completed
- Registry status
- Phase 3
- Development phase
- 502
- Enrollment target
NCT04229004 is a Phase 3 study that has completed, run by Pancreatic Cancer Action Network. The registered enrollment target is 502 participants.
The verdict
NCT04229004, a Phase 3 study, has completed, sponsored by Pancreatic Cancer Action Network.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 502 participants
- Enrollment target
Study Summary
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. Primary Objectives * To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in first and/or second line metastatic ductal adenocarcinoma (metastatic pancreatic cancer) participants and determine which, if any, participants benefit from each investigational arm. Secondary Objectives * To determine short and long-term safety signals of each investigational arm in metastatic pancreatic cancer participants vs. SOC. * To determine progression-free survival (PFS) for each investigational arm vs. SOC. * To determine rates of overall response, CR, and PR; duration of overall response, CR or PR (whichever occurs first). * To determine rates of clinical benefit; duration of clinical benefit.
Interventions
- DRUG Gemcitabine combined with nab-paclitaxel
- DRUG Dose -mFOLFIRINOX
- DRUG Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel
- DRUG Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine
- DRUG Drug: Dose -SM-88
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 502 participants |
| Start Date | 2020-01-31 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04229004
The ClinicalTrials.gov registry entry for NCT04229004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 502 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pancreatic Cancer Action Network, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Gemcitabine combined with nab-paclitaxel is the first listed.
NCT04229004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04229004 about?
NCT04229004 is a clinical study titled "A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer". Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. Primary Objectives * To compare each investigational arm versus standard of care (SOC) for superiority in overall survival in first and/or second line meta...
What is the current status of trial NCT04229004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 502 participants. The study started on 2020-01-31. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT04229004?
The interventions under investigation include: Gemcitabine combined with nab-paclitaxel (DRUG), Dose -mFOLFIRINOX (DRUG), Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel (DRUG), Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine (DRUG), Drug: Dose -SM-88 (DRUG).
Who is sponsoring clinical trial NCT04229004?
This trial is sponsored by Pancreatic Cancer Action Network, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.